

Actinium Pharmaceuticals, Inc.

Form 3/A

August 22, 2013

**FORM 3****UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104

Expires: January 31, 2005

Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting  
Person \*

Â TRAVERSA SERGIO

(Last) (First) (Middle)

100 DAIBES COURT APT. 1404

(Street)

EDGEWATER, Â NJ Â 07020

(City) (State) (Zip)

2. Date of Event Requiring  
Statement

(Month/Day/Year)

12/28/2012

3. Issuer Name and Ticker or Trading Symbol

Actinium Pharmaceuticals, Inc. [ATNM]

4. Relationship of Reporting  
Person(s) to Issuer

(Check all applicable)

☒ Director ☐ 10% Owner☒ Officer ☐ Other

(give title below) (specify below)

Interim CEO &amp; Interim CFO

5. If Amendment, Date Original  
Filed(Month/Day/Year)

01/03/2013

6. Individual or Joint/Group

Filing(Check Applicable Line)

☒ Form filed by One Reporting  
Person☐ Form filed by More than One  
Reporting Person**Table I - Non-Derivative Securities Beneficially Owned**1. Title of Security  
(Instr. 4)2. Amount of Securities  
Beneficially Owned  
(Instr. 4)3. Ownership  
Form:  
Direct (D)  
or Indirect  
(I)  
(Instr. 5)4. Nature of Indirect Beneficial  
Ownership  
(Instr. 5)

Common Stock

0

D

Â

Reminder: Report on a separate line for each class of securities beneficially  
owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of  
information contained in this form are not  
required to respond unless the form displays a  
currently valid OMB control number.****Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**1. Title of Derivative Security  
(Instr. 4)2. Date Exercisable and  
Expiration Date  
(Month/Day/Year)

Date Exercisable Expiration Date

3. Title and Amount of  
Securities Underlying  
Derivative Security  
(Instr. 4)Title Amount or  
Number of4. Conversion  
or Exercise  
Price of  
Derivative  
Security5. Ownership  
Form of  
Derivative  
Security:  
Direct (D)  
or Indirect6. Nature of Indirect  
Beneficial Ownership  
(Instr. 5)

# Edgar Filing: Actinium Pharmaceuticals, Inc. - Form 3/A

Shares

(I)  
(Instr. 5)

Options to purchase  
common stock      Â (1)      08/30/2022      Options      49,950      \$ 1.5      D      Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
TRAVERSA SERGIO 100 DAIBES COURT APT. 1404 EDGEWATER, NJ 07020	Â X	Â	Â Interim CEO & Interim CFO	Â

## Signatures

/s/ Sergio  
Traversa      08/22/2013

Signature of  
Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Options granted on August 30, 2012 to purchase an aggregate of 49,950 shares of common stock. A total of 28% of the options will vest one year from the grant date, and 2% per month thereafter.

Â

### Remarks:

Mr. Traversa was appointed as the company's (i) interim Chief Executive Officer on March 1, 2013

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.